SBI Securities Co. Ltd. Purchases Shares of 1,139 Illumina, Inc. (NASDAQ:ILMN)

SBI Securities Co. Ltd. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,139 shares of the life sciences company’s stock, valued at approximately $152,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the fourth quarter worth about $32,000. TD Private Client Wealth LLC lifted its stake in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of Illumina by 73.5% in the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after acquiring an additional 186 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on ILMN shares. Canaccord Genuity Group cut their price target on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Citigroup cut their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Royal Bank of Canada cut their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Stock Up 2.3 %

NASDAQ:ILMN opened at $86.62 on Friday. The firm has a market capitalization of $13.72 billion, a PE ratio of -11.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock has a 50 day moving average of $118.38 and a 200-day moving average of $131.50. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.